A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray (200 mg, Once Daily), in the Treatment of Seasonal Allergic Rhinitis (SAR) in Patients 18 Years and Older

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2004
The primary objective of this placebo-controlled EEC study is to determine the time to onset of action of ciclesonide, applied as a nasal spray (200 mg, once daily) in patients with SAR.
Epistemonikos ID: 874f655e9ad70ac569bc40aa7708427ae0c9ac85
First added on: May 05, 2024